Combining zoledronic acid with anti-PD-L1 therapy reduces PD-L1+ TAM infiltration and alleviates CD8+ T cell suppression, potentially enhancing therapy efficacy in HCC [107]. Here, CD8A is linked to hepatocellular carcinoma.